Bispecific Antibodies Like Zanidatamab Have Promise in Heavily Pretreated HER2+ Breast Cancer
December 23rd 2021Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate HER2-directed bispecific antibodies in HER2-positive breast cancer, the emergence of zanidatamab as a potential treatment strategy, and the unmet medical need the agent could fill in this disease.
Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm
Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.
Toxicity Management Remains Key With Expanding Frontline Treatment Options in Lung Cancer
October 25th 2021Antoinette Wozniak, MD, FACP, FASCO, highlights the importance of monitoring patients with lung cancer for toxicities and significant advances on the horizon that are expected to further expand the lung cancer armamentarium.
Novel Vaccine Combos Represent a Promising Treatment Approach in Breast Cancer
July 19th 2021The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.
New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward
January 20th 2021Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.
Updated ExteNET Data Raise Questions Over TKI Utility in HER2+ Breast Cancer With Brain Metastases
January 6th 2021Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.
Hematology: Chaired by Mounzer E. Agha, MD
November 10th 2020Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of hematologic oncology.
Precision Medicine: Chaired by Jason Luke, MD
October 22nd 2020Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of oncology.
Pitt & UPMC Hillman Cancer Center Name New Leader of Surgical Oncology
September 25th 2020Following an extensive national search, Amer Zureikat, MD, FACS, has been appointed vice chair of surgery for Surgical Oncology in the Department of Surgery at UPMC and chief of Surgical Oncology at UPMC Hillman Cancer Center.
Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
June 4th 2020In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.